The company's asset base expanded significantly to Rs 28,462 crore after it brought 2.1 GWh of storage online during the quarter. This addition elevated total storage capacity to 5.2 GWh, securing the firm's position as India's second-largest operator in the segment. Strong execution also yielded near-perfect plant and grid availability rates above 99% alongside a 19.6% boost in generated power units.
Key points
ACME Solar increased its full-year storage commissioning target from 10 GWh to more than…: ACME Solar increased its full-year storage commissioning target from 10 GWh to more than 12 GWh.
Subsidiary ACME Marigold Urja secured a 25-year power purchase deal with NTPC at Rs 4.37…: Subsidiary ACME Marigold Urja secured a 25-year power purchase deal with NTPC at Rs 4.37 per unit.
The 400 MW firm and dispatchable renewable power supply project is scheduled to begin com…: The 400 MW firm and dispatchable renewable power supply project is scheduled to begin commercial operations by June 2028.
Sources checked by our analysis pipeline: 1
The company in a filing with the exchange said that the profit after tax (PAT) increased by 133.5% for the quarter and stood at Rs 269 crore with a margin of 26.7%. The PAT in Q2FY26 was Rs 115 crore.
Also Read | City Union Bank shares rally 7% after Q2 net profit grows 27% YoY to Rs 416 Crore
The revenue increased by 67.5% for the quarter (y-o-y basis) to Rs 1,007 crore in Q2FY27 from Rs 601 crore in Q2 FY26, primarily driven by BESS and RE capacity addition. EBITDA margin of 86.7% for the quarter, marginally lower YoY as it also includes cost of power purchased for BESS operations under operating expenses.
The asset base stands at Rs 28,462 crore, up Rs 11,466 crore from last year on account of commissioning of BESS and RE assets. The company commissioned 2.1 GWh BESS for the quarter till date, taking total commissioned BESS capacity to 5.2 GWh – 2nd largest BESS capacity in India. It commissioned BESS and solar enabled partial commissioning of 1.9 GW projects and the initial…
Strong domestic performance at the flagship burger chain helped bolster corporate profits despite persistent revenue pressures elsewhere in the portfolio. Fast-food competitors leveraging aggressive promotional discounts have continued to lure diners away from the company's chicken division. Consequently, executives are refining operational efficiency and core menu offerings to stabilize struggling banners.
Robust commercial adoption of novel cancer therapies and vaccines is reinforcing the drugmaker's financial cushion against looming exclusivity losses. Growth across core pharmaceutical lines offset softer performance within the veterinary business, providing sufficient momentum to absorb significant transaction costs. This operational resilience positions the enterprise to aggressively defend its primary oncology franchise ahead of key patent expirations.
Robust quarterly execution has bolstered the energy group's near-term operational standing across its core markets. However, mounting capital expenditures at the key Dutch facility threaten to weigh on long-term project returns and cash allocation. Stakeholders now face a delicate balance between immediate profitability and the expanding financial commitments required to complete major infrastructure developments.